Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia.

Abstract

Oxcarbazepine, a new drug with antineuralgic properties has been evaluated in a long-term follow-up of 6 patients (2 males, 4 females; aged 42-77 years; mean 61 years), previously reported on with trigeminal neuralgia. Daily oral oxcarbazepine dose correlated significantly with both total oxcarbazepine (r = 0.851) and 10-OH-carbazepine (r = 0.958) serum concentrations. Mean percent free oxcarbazepine and 10-OH-carbazepine was 41 and 61% respectively and there was no significant difference in binding between male and female patients. Free serum concentrations of oxcarbazepine and 10-OH-carbazepine correlated significantly with total serum oxcarbazepine and 10-OH-carbazepine respectively, indicating that binding capacity of both are essentially constant within the respective ranges of 0.2-11.4 mumol.l-1 and 20-150 mumol.l-1 observed in the present study.

• Authors: P N Patsalos, A A Elyas, J M Zakrzewska
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 39 Issue 4 Pg. 413-5 ( 1990) ISSN: 0031-6970 [Print] Germany
• PMID: 2076729 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 10,11-dihydro-10-hydroxycarbamazepine
• Blood Proteins
• Carbamazepine
• Oxcarbazepine

Topics

• Adult
• Aged
• Blood Proteins (metabolism)
• Carbamazepine (analogs & derivatives, metabolism)
• Female
• Humans
• Male
• Middle Aged
• Oxcarbazepine
• Protein Binding
• Trigeminal Neuralgia (metabolism)